Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Shandong Simcere Biopharmaceutical Co., Ltd.

Hainan Simcere Pharmaceutical Co., Ltd.

Yayuan Fu

Weikang Tao

Zhuoxiao Cao

Lianshan Zhang

Qiyue Hu

Piaoyang Sun

Ling L Zhang

Dongbing Cui

Jiajian Liu

Yingying Hu

Renhong Tang

Jinsheng Ren

Ying Zhang

Ting Ting Zhang

Zhen Zhang

Hu Ge

Yali Wang

Yifang Wang

Ling Zhang

Jindong Liang

Jianyan Xu

Guiyang Jiang

Junzhuan Qiu

Ziyong Sun

Jiping Zha

Jingping Wei

Haoying Zhang

Dong Ma

The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2Rβγ complexes compared to wild-type IL-2.

Il-2 mutant and application thereof

IL-2 mutant and application thereof

Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof

A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.

TIGIT antibody, antigen-binding fragment thereof, and medical use thereof

A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3-related conditions.

TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof

Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.

Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof

Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).

Anti-sclerostin antibody, antigen binding fragment and medical use thereof

Growing community of inventors

Shanghai, China

Yayuan Fu